Modeling time to cure after short-duration treatment for chronic HCV with daclatasvir, asunaprevir, beclabuvir and sofosbuvir: the FOURward study

被引：0
|
作者：
Deng, B. [1 ]
Lou, S. [1 ]
Dubey, P. [1 ]
Etzion, O. [2 ]
Chayam, K. [3 ]
Uprichard, S. L. [1 ]
Sulkowski, M. [4 ]
Cotler, S. J. [1 ]
Dahari, H. [1 ]
机构：
[1] Loyola Univ, Med Ctr, Dept Med, Maywood, CA USA
[2] Soroka Univ Med Ctr, Beer Sheva, Israel
[3] Hiroshima Univ, Dept Gastroenterol & Metab, Hiroshima, Japan
[4] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF VIRAL HEPATITIS | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1-069
引用
收藏
页码：58 / 58
页数：1
相关论文
共 14 条
  • [1] Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)
    Sulkowski, Mark S.
    Flamm, Steve
    Kayali, Zeid
    Lawitz, Eric J.
    Kwo, Paul
    McPhee, Fiona
    Torbeyns, Anne
    Hughes, Eric A.
    Swenson, Eugene S.
    Yin, Philip D.
    Linaberry, Misti
    LIVER INTERNATIONAL, 2017, 37 (06) : 836 - 842
  • [2] Short-duration therapy with daclatasvir/asunaprevir/beclabuvir fixed-dose combination plus sofosbuvir in patients with chronic hepatitis C genotype 1 (FOURward Study)
    Sulkowski, Mark S.
    Flamm, Steven L.
    Kayali, Zeid
    Lawitz, Eric
    Kwo, Paul Y.
    McPhee, Fiona
    Torbeyns, Anne
    Hughes, Eric A.
    Swenson, Eugene S.
    Yin, Philip
    Linaberry, Misti
    HEPATOLOGY, 2015, 62 : 556A - 556A
  • [3] Daclatasvir plus asunaprevir plus beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients
    Everson, Gregory T.
    Sims, Karen D.
    Thuluvath, Paul J.
    Lawitz, Eric
    Hassanein, Tarek
    Rodriguez-Torres, Maribel
    Desta, Tadesse
    Hawkins, Trevor
    Levin, James M.
    Hinestrosa, Federico
    Rustgi, Vinod
    Schwartz, Howard
    Younossi, Zobair
    Webster, Lynn
    Gitlin, Norman
    Eley, Timothy
    Huang, Shu-Pang
    McPhee, Fiona
    Grasela, Dennis M.
    Gardiner, David F.
    LIVER INTERNATIONAL, 2016, 36 (02) : 189 - 197
  • [4] HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
    Canini, Laetitia
    Imamura, Michio
    Kawakami, Yoshiiku
    Uprichard, Susan L.
    Cotler, Scott J.
    Dahari, Harel
    Chayama, Kazuaki
    PLOS ONE, 2017, 12 (12):
  • [5] Short-Duration Sofosbuvir/Velpatasvir Safe and Effective in Treating HCV Infection Immediately after Liver Transplant
    Gane, Edward J.
    Beckmann, Andrea
    Hyland, Robert
    Arterburn, Sarah
    Svarovskaia, Evguenia
    Massetto, Benedetta
    Brainard, Diana
    Munn, Stephen
    HEPATOLOGY, 2018, 68 : 359A - 359A
  • [6] HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
    Dahari, Harel
    Canini, Laetitia
    Graw, Frederik
    Uprichard, Susan L.
    Araujo, Evaldo S. A.
    Penaranda, Guillaume
    Coquet, Emilie
    Chiche, Laurent
    Riso, Aurelie
    Renou, Christophe
    Bourliere, Marc
    Cotler, Scott J.
    Halfon, Philippe
    JOURNAL OF HEPATOLOGY, 2016, 64 (06) : 1232 - 1239
  • [7] Modeling HCV cure after an ultra-short duration of therapy with direct acting agents
    Goyal, Ashish
    Lurie, Yoav
    Meissner, Eric G.
    Major, Marian
    Sansone, Natasha
    Uprichard, Susan L.
    Cotler, Scott J.
    Dahari, Harel
    ANTIVIRAL RESEARCH, 2017, 144 : 281 - 285
  • [8] SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY
    Matthews, Gail
    Bhagani, Sanjay
    Van der Valk, Marc
    Rockstroh, Juergen K.
    Kim, Arthur Y.
    Thurnheer, Christine
    Feld, Jordan J.
    Bruneau, Julie
    Gane, Edward J.
    Hellard, Margaret
    Grebely, Jason
    Applegate, Tanya
    Marks, Pip
    Martinello, Marianne
    Petoumenos, Kathy
    Dore, Gregory
    HEPATOLOGY, 2019, 70 (06) : 1487A - 1488A
  • [9] Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study
    Chua, Joel, V
    Ntem-Mensah, Afua
    Abutaleb, Ameer
    Husson, Jennifer
    Mutumbi, Lydiah
    Lam, Ka Wing
    Ghosh, Alip
    Romani, Sara
    Poonia, Bhawna
    Lee, Sam
    Pascual, M. Luz
    Frumkin, Lyn R.
    Kottilil, Shyamsundaran
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (06) : 3752 - 3760
  • [10] Thermal latency adds to lesion depth after application of high-power short-duration radiofrequency energy: Results of a computer-modeling study
    Irastorza, Ramiro M.
    d'Avila, Andre
    Berjano, Enrique
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2018, 29 (02) : 322 - 327
12